Skip to content
UpLiftRx
MedicationsLabsProvidersVisitsOrdersDashboardSign in
UpLiftRx
MedicationsLabsProvidersVisitsOrdersDashboard
Sign in
← All articles
Weight Loss

Semaglutide vs. Tirzepatide: How They Differ and How to Choose

A plain-English comparison of the two leading GLP-1 weight-loss medications — mechanism, expected weight loss, side effects, dosing, cost, and how a clinician decides which one is right for you.

Woman in navy athletic wear walking on a tree-lined path in morning light
Reviewed by UpLiftRx clinical team · Published June 1, 2026

Semaglutide and tirzepatide are the two most prescribed weight-management medications in the United States. Both quiet appetite, slow gastric emptying, and improve metabolic markers — but they work through slightly different receptors and produce different magnitudes of weight loss in clinical trials.

The short answer

Semaglutide is a single-receptor GLP-1 agonist. Tirzepatide is a dual GLP-1/GIP agonist — it acts on two appetite-regulating receptors instead of one. In head-to-head and indirect comparisons, tirzepatide tends to produce more weight loss on average, but semaglutide remains highly effective and is appropriate for most patients starting a weight-management program.

How they work

Both medications mimic gut hormones (incretins) that are released after a meal. They signal your brain that you're full, slow digestion so you feel full longer, and improve insulin sensitivity. Tirzepatide additionally activates GIP, a related incretin that further enhances appetite suppression and metabolic effects.

Expected weight loss

In published phase 3 trials, semaglutide 2.4 mg weekly produced average weight loss of about 15% of body weight over 68 weeks. Tirzepatide 10–15 mg weekly produced average weight loss of about 20–22% over a similar duration. Individual results vary substantially with dose, adherence, lifestyle, and biology.

Side effects

The most common side effects of both medications are gastrointestinal: nausea, constipation, diarrhea, and reflux, usually most pronounced during dose increases and improving with time. Slow titration, hydration, smaller meals, and adequate fiber and protein reduce these effects substantially.

Who should not take them

Neither medication is appropriate if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, a history of pancreatitis, or are pregnant, breastfeeding, or trying to conceive. Your clinician screens for these and additional contraindications during intake.

Compounded vs brand

Brand-name semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®) are FDA-approved. Compounded drugs are not FDA-approved, are not generics, and may differ in ingredient form, concentration, excipients, and other characteristics. Your clinician will discuss whether a legally available compounded preparation is appropriate for your specific clinical need.

Quick answers

Is tirzepatide more effective than semaglutide?

On average, yes — published trials show tirzepatide produces greater weight loss at maximum dose. But effectiveness varies by person, and semaglutide remains highly effective for most patients. Your clinician chooses based on your health, goals, side effects, and access.

Can I switch from one to the other?

Yes, under clinician guidance. Switching typically involves stopping the first medication and re-titrating from a low starting dose of the second to manage gastrointestinal side effects.

How long do I take them?

Both are designed for long-term use; stopping typically results in weight regain as appetite returns toward baseline. Many patients maintain results on a lower maintenance dose with clinician guidance.

Talk to a clinician

Get a personalized care plan.

A U.S.-licensed clinician reviews your intake and follows up in your portal.

Start your consultation →
Transparency
  • Company
  • Our clinicians
  • Pharmacy partners
  • Where we operate
  • Accreditation
Legal
  • Terms of Service
  • Privacy Policy
  • Notice of Privacy Practices
  • Telehealth Consent
  • Auto-Renewal Terms
  • Refund & Shipping
  • Pharmacy Disclosure
  • Prescribing Policy
  • Patient Rights & Nondiscrimination
  • Texas Medical Board Complaint Notice
  • SMS Terms
  • Cookies
  • California Privacy
  • Accessibility
Support
  • support@upliftrx.co
  • Member sign in

Medical emergency? Call 911. In crisis? Call or text 988 (Suicide & Crisis Lifeline). UpLiftRX is not for emergencies.

Prescription products require an online consultation with an independent, licensed clinician, who decides whether treatment is appropriate. Available to adults 18+ in states where our clinicians are licensed.

Compounded medications are prepared by state-licensed pharmacies for an individual patient and are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed.

Latitude Investments Management Ltd. Liability Co. d/b/a UpLiftRX provides a technology platform and is not a pharmacy or a medical provider. Medical services are provided by independent, licensed clinicians of a professional medical group (being finalized). Prescriptions are dispensed by independent, state-licensed pharmacies. Latitude Investments Management Ltd. Liability Co., a Wyoming limited liability company (filing no. 2024-001499647), 5709 Gardendale Dr, STE D, Houston, TX 77092.

Wegovy® and Saxenda® are registered trademarks of Novo Nordisk A/S. Zepbound® and Cialis® are registered trademarks of Eli Lilly and Company. Contrave® is a registered trademark of Currax Pharmaceuticals LLC. Viagra® is a registered trademark of Viatris Specialty LLC. All trademarks are the property of their respective owners. UpLiftRX is not affiliated with or endorsed by any drug manufacturer, and generic medications are not the brand-name products.

© 2026 Latitude Investments Management Ltd. Liability Co. d/b/a UpLiftRX.